ClinicalTrials.gg

Program

survodutide

Also written as “Survodutide”, “BI 456906” and “Survodutide formulation A”.

In Boehringer Ingelheim's pipeline, GCGR/GLP1 agonist. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Fatty Liver · Liver Cirrhosis · Renal Insufficiency, led by Boehringer Ingelheim.

Furthest: phase 3, since Sep 27, 202335 company-led studies, 10 open or runningNext primary completion: Dec 8, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim3510 open or runningphase 3since Sep 27, 2023Jun 1, 2017Dec 8, 2026phase 1 · NCT07768813
  • Named in Boehringer Ingelheim’s own pipeline as Survodutide (BI 456906), phase 3, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Jun 1, 2017.

  1. Apr 3, 20242 phase 1 studiesNCT06352424, NCT06352411
  2. Jul 1, 2024Phase 1 study in OverweightNCT06492135 · 30 enrolled · China
  3. Aug 20, 2024Phase 1 study in OverweightNCT06564441 · 34 enrolled · Belgium
  4. Oct 8, 20242 phase 3 studiesNCT06632457, NCT06632444
  5. Dec 19, 2024Phase 1 study in ObesityNCT06745284 · 64 enrolled · United States
  6. Jan 10, 2025Phase 1 study in HealthyNCT06772532 · 30 enrolled · Germany
  7. Jul 16, 2025Phase 1 study in HealthyNCT07071974 · 16 enrolled · Germany
  8. Oct 27, 2025Phase 1 study in HealthyNCT07221591 · 100 enrolled · Germany
  9. Feb 10, 2026Phase 1 study in ObesityNCT07413913 · 56 enrolled · Germany
  10. Aug 5, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07754461 · 600 planned · United States, Australia, Canada and more
  11. Aug 12, 2026Phase 1 study in ObesityNCT07768813 · 44 enrolled · Germany
  12. Sep 25, 20263 phase 3 studies in ObesityNCT07850063, NCT07850050, NCT07855900
  13. Oct 27, 2026Primary completion moved from 2028-06-25 to 2029-11-06Date moved laterphase 3 · +16 months · NCT07855900
  14. Nov 9, 2026Phase 1 study in ObesityNCT07940244 · 80 planned · Germany

Ahead

  1. Nov 1, 2026Primary completion: phase 1 study in ObesityNCT06745284
  2. Dec 8, 2026Primary completion: phase 1 study in ObesityNCT07768813
  3. Jan 6, 2027Primary completion: phase 1 study in ObesityNCT05202353
  4. Oct 31, 2027Primary completion: phase 1 study in ObesityNCT07940244

TargetBeta

“GCGR/GLP1 agonist”the company's pipeline, read by Claude · source
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
DR10624ruleHuadong Medicinephase 36
efinopegdutideJohnson & Johnsonphase 215
AZD9550AstraZenecaphase 27
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07940244Obesity · Germany1Not yet recruitingOct 31, 202780
NCT07855900Obesity · United States3Not yet recruitingNov 6, 2029350
NCT07850063Obesity · United States, China, Germany and more3Not yet recruitingApr 29, 2029600
NCT07850050Obesity · United States, United Kingdom3Not yet recruitingJul 26, 2028600
NCT07768813Obesity · Germany1Active, not recruitingDec 8, 202644
NCT07754461Diabetes Mellitus, Type 2 · United States, Australia, Canada and more3RecruitingJan 17, 2028600
NCT07413913Obesity · Germany1CompletedMay 28, 202656
NCT07221591Healthy · Germany1CompletedJul 28, 2026100
NCT07071974Healthy · Germany1CompletedOct 7, 202516
NCT06772532Healthy · Germany1CompletedMay 29, 202530
NCT06745284Obesity · United States1Active, not recruitingNov 1, 202664
NCT06632457Metabolic Dysfunction Associated Steatohepatitis · United States, Argentina, Australia and more3RecruitingJun 5, 20291,590
NCT06632444Liver Cirrhosis · United States, Argentina, Australia and more3RecruitingDec 27, 20311,800
NCT06564441Overweight · Belgium1CompletedDec 16, 202534
NCT06492135Overweight · China1CompletedApr 15, 202530
NCT06352424Obesity · Germany1CompletedFeb 24, 202523
NCT06352411Renal Insufficiency · Germany1CompletedSep 16, 202542
NCT06309992Obesity · United States, Spain3CompletedOct 9, 2025218
NCT06214741Obesity · China3CompletedJul 29, 2025307
NCT06200467Overweight · Germany1CompletedOct 22, 2025110
NCT06176365Obesity · Japan3CompletedDec 3, 2025274
NCT06077864Obesity · United States, Argentina, Australia and more3CompletedJun 1, 20265,530
NCT06066528Obesity · United States, Australia, Belgium and more3CompletedDec 12, 2025755
NCT06066515Obesity · United States, Australia, Belgium and more3CompletedDec 2, 2025726
NCT05896384Healthy · Germany1CompletedFeb 14, 202532
NCT05751226Obesity · Germany1CompletedAug 1, 202488
NCT05421338Healthy · Netherlands1CompletedNov 17, 20226
NCT05296733Liver Diseases · United States, Germany, Hungary and more1CompletedDec 29, 202382
NCT05202353Obesity · Netherlands1Active, not recruitingJan 6, 202729
NCT04771273Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more2CompletedNov 9, 2023295
NCT04667377Obesity · United States, Australia, Belgium and more2CompletedSep 15, 2022387
NCT04384081Healthy · Japan1CompletedNov 17, 202037
NCT04153929Diabetes Mellitus, Type 2 · United States, Australia, Austria and more2CompletedOct 8, 2021413
NCT03591718Obesity · Germany1CompletedApr 20, 2020131
NCT03175211Healthy · Germany1CompletedFeb 19, 201820

How it is read

Names in the registry

  • “Survodutide”, 12 entries
  • “BI 456906”, 12 entries
  • “survodutide”, 5 entries
  • “Survodutide formulation A”, 3 entries
  • “Survodutide formulation B2”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.